jump to content jump to footer

Potential of using structured data from clinical trials and routine for AI and radiomics research

Dr. Nils Grosse Hokamp shares his experience of using mint Lesion™ at the University Hospital Cologne in this brief interview. He talks about how they have expanded their usage of mint Lesion™ over the years, how it has changed their clinical studies, and his view on the potential of structured data for research.

Video Clinical Trials Standardized Reading Procedures Clinical Routine Therapy Response Assessment AI Radiomics Structured Reporting

Related Resources

mint Lesion usage during a clinical trial read, featuring the TGRM export tool.
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer

For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…

Participants at the RECIST and Beyond workshop in Cologne during hands-on training with mint Lesion for structured tumor response assessment.
The two-day “RECIST and Beyond” workshop at radCIO Cologne offered intensive hands-on training on RECIST, iRECIST, mRECIST and LI-RADS, with real-case reporting performed directly in mint Lesion.
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging

How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?

Screenshot of the mint Lesion interface showing RANO 2.0 configuration, tumor burden calculations, and structured neuro-oncology assessment tools.
mint Lesion fully supports RANO 2.0 implementation with configurable parameters, automated tumor burden calculations, and structured workflows for neuro-oncology clinical trials.
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion

Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…